In the journey to outperform the market, investors delve into the art of stock selection. Choosing the right stocks can be a powerful driver for wealth accumulation.
In the latest session, Praxis Precision Medicines Inc (NASDAQ: PRAX) closed at $171.75 down -5.63% from its previous closing price of $181.99. In other words, the price has decreased by -$5.63 from its previous closing price. On the day, 0.67 million shares were traded. PRAX stock price reached its highest trading level at $186.6 during the session, while it also had its lowest trading level at $171.74.
Ratios:
For a deeper understanding of Praxis Precision Medicines Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 6.31 and its Current Ratio is at 6.31. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
On May 07, 2025, Chardan Capital Markets started tracking the stock assigning a Buy rating and target price of $80.
H.C. Wainwright reiterated its Buy rating for the stock on March 03, 2025, while the target price for the stock was revised from $120 to $105.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Nov 14 ’24 when Nemiroff Alex sold 8,239 shares for $80.20 per share. The transaction valued at 660,827 led to the insider holds 10,301 shares of the business.
Mastrocola Lauren sold 5,188 shares of PRAX for $424,318 on Nov 14 ’24. The Principal Accounting Officer now owns 5,613 shares after completing the transaction at $81.78 per share. On Nov 14 ’24, another insider, Mastrocola Lauren, who serves as the Officer of the company, bought 5,189 shares for $81.77 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, PRAX now has a Market Capitalization of 4274879488 and an Enterprise Value of 3314092800. For the stock, the TTM Price-to-Sale (P/S) ratio is 535.42 while its Price-to-Book (P/B) ratio in mrq is 8.94. Its current Enterprise Value per Revenue stands at 426.799 whereas that against EBITDA is -12.213.
Stock Price History:
The Beta on a monthly basis for PRAX is 2.98, which has changed by 1.5322108 over the last 52 weeks, in comparison to a change of 0.15566266 over the same period for the S&P500. Over the past 52 weeks, PRAX has reached a high of $206.71, while it has fallen to a 52-week low of $26.70. The 50-Day Moving Average of the stock is 99.03%, while the 200-Day Moving Average is calculated to be 196.20%.
Shares Statistics:
For the past three months, PRAX has traded an average of 804.20K shares per day and 847620 over the past ten days. A total of 24.19M shares are outstanding, with a floating share count of 22.77M. Insiders hold about 5.88% of the company’s shares, while institutions hold 98.13% stake in the company. Shares short for PRAX as of 1760486400 were 2611630 with a Short Ratio of 3.25, compared to 1757894400 on 2383700. Therefore, it implies a Short% of Shares Outstanding of 2611630 and a Short% of Float of 12.36.
Earnings Estimates
The stock of Praxis Precision Medicines Inc (PRAX) is currently being evaluated by 12.0 analysts who are actively contributing to its market rating.The consensus estimate for the next quarter is -$3.42, with high estimates of -$2.79 and low estimates of -$4.25.
Analysts are recommending an EPS of between -$12.47 and -$14.65 for the fiscal current year, implying an average EPS of -$13.51. EPS for the following year is -$12.91, with 12.0 analysts recommending between -$5.4 and -$19.17.
